Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Cash Flows

v3.25.2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Cash flows from operating activities:    
Consolidated net loss $ (18,377) $ (24,907)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:    
Share-based compensation 1,530 2,038
Amortization of intangible assets 20 20
Amortization of finance lease right-of-use assets 271 271
Amortization of operating lease right-of-use assets 351 321
Depreciation of fixed assets 484 638
Gain on sale of fixed assets   4,909
Gain on extinguishment of debt   (808)
Accrued interest receivable on promissory note receivable (62) (88)
Amortization of deferred financing costs   120
Impairment of fixed assets   3,100
Gain on sale of intangible assets   (1,000)
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (408) 214
Security deposit   24
Accounts payable 1,831 (1,491)
Accrued expenses (758) (1,726)
Operating lease obligations (436) (389)
Contract liabilities 250 200
Net cash used in operating activities (15,304) (18,554)
Cash flows from investing activities:    
Payment received for interest and principal on promissory note receivable 758  
Sale proceeds for intangible assets   1,000
Purchase of fixed assets (16) (210)
Sales proceeds for fixed assets   116
Net cash provided by investing activities 742 906
Cash flows from financing activities:    
Proceeds from sales of common stock 3,541 25,523
Proceeds from Warrant Inducement 6,246  
Payments made for costs to acquire capital (294) (88)
Payments for fractional shares after reverse stock split   (7)
Proceeds from the exercise of stock options 131  
Subscription receivable   204
Payment of equipment financing loan (178) (160)
Proceeds from term promissory note   895
Payment of term promissory note (218) (88)
Payment of term note payable   (1,513)
Payment of finance lease obligation (299) (272)
Net cash provided by financing activities 8,929 24,494
Net (decrease) increase in cash, cash equivalents and restricted cash (5,633) 6,846
Cash, cash equivalents and restricted cash - beginning 14,425 7,579
Cash, cash equivalents and restricted cash - end 8,792 14,425
Schedule of non-cash activities:    
Indefinite-lived intangible asset addition 1,500  
Shares issued to AstralBio for license fee (750)  
Credit provided by AstralBio (750)  
Insurance premium financing   669
Subscription receivable 105  
Costs to raise capital paid directly from gross proceeds 81 1,467
Costs to raise capital included in accrued expenses 75 308
Issuance of warrant for term note payable obligation   4,499
Reserves related to term promissory note included in prepaid expenses   109
Costs related to tern promissory note paid directly from gross proceeds   68
Supplemental cash flow information:    
Cash paid during the period for interest $ 212 $ 749